BELLUS Wellness to discontinue NC-503 diabetes development program BELLUS Wellness declared today that it’ll discontinue its NC-503 diabetes development system following the outcomes of the recently finished Stage IIa clinical proof-of-concept research evaluating NC-503 as cure for Type 2 diabetes more info . The analysis didn’t meet its major efficacy endpoint. While we have been disappointed that the NC-503 indication for Type 2 Diabetes didn’t end up being effective, our decision today allows us to protect shareholder worth and conserve our economic and recruiting for projects that people believe have high prospect of achievement, said Roberto Bellini, President and CEO of BELLUS Health.